Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V)

NCT04959344 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Klebsiella Pneumoniae Infection

Interventions

BIOLOGICAL: Kleb4V target dose
BIOLOGICAL: Kleb4V target dose + AS03
BIOLOGICAL: Kleb4V low dose
BIOLOGICAL: Kleb4V low dose + AS03
BIOLOGICAL: Placebo

Sponsor

LimmaTech Biologics AG

Collaborators

[object Object]